These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8807831)

  • 41. From form to function: signaling by protein tyrosine phosphatases.
    Tonks NK; Neel BG
    Cell; 1996 Nov; 87(3):365-8. PubMed ID: 8898190
    [No Abstract]   [Full Text] [Related]  

  • 42. In vitro characterization of major ligands for Src homology 2 domains derived from protein tyrosine kinases, from the adaptor protein SHC and from GTPase-activating protein in Ramos B cells.
    Baumann G; Maier D; Freuler F; Tschopp C; Baudisch K; Wienands J
    Eur J Immunol; 1994 Aug; 24(8):1799-807. PubMed ID: 7519995
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hematopoietic cell phosphatase, SHP-1, is constitutively associated with the SH2 domain-containing leukocyte protein, SLP-76, in B cells.
    Mizuno K; Katagiri T; Hasegawa K; Ogimoto M; Yakura H
    J Exp Med; 1996 Aug; 184(2):457-63. PubMed ID: 8760799
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The N-terminal SH2 domain of the tyrosine phosphatase, SHP-2, is essential for Jak2-dependent signaling via the angiotensin II type AT1 receptor.
    Godeny MD; Sayyah J; VonDerLinden D; Johns M; Ostrov DA; Caldwell-Busby J; Sayeski PP
    Cell Signal; 2007 Mar; 19(3):600-9. PubMed ID: 17027227
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tyrosine phosphatase SHP-2 binding to CTLA-4: absence of direct YVKM/YFIP motif recognition.
    Schneider H; Rudd CE
    Biochem Biophys Res Commun; 2000 Mar; 269(1):279-83. PubMed ID: 10694513
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early signaling events triggered by peroxovanadium [bpV(phen)] are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase(s) by bpV(phen).
    Band CJ; Posner BI; Dumas V; Contreres JO
    Mol Endocrinol; 1997 Dec; 11(13):1899-910. PubMed ID: 9415395
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phosphopeptide ligands of the SHP-1 N-SH2 domain: effects on binding and stimulation of phosphatase activity.
    Hampel K; Kaufhold I; Zacharias M; Böhmer FD; Imhof D
    ChemMedChem; 2006 Aug; 1(8):869-77. PubMed ID: 16902940
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dephosphorylation of ZAP-70 and inhibition of T cell activation by activated SHP1.
    Brockdorff J; Williams S; Couture C; Mustelin T
    Eur J Immunol; 1999 Aug; 29(8):2539-50. PubMed ID: 10458769
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune signalling: SHP-2 docks at multiple ports.
    Huyer G; Alexander DR
    Curr Biol; 1999 Feb; 9(4):R129-32. PubMed ID: 10074424
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Leptin receptor activation of SH2 domain containing protein tyrosine phosphatase 2 modulates Ob receptor signal transduction.
    Li C; Friedman JM
    Proc Natl Acad Sci U S A; 1999 Aug; 96(17):9677-82. PubMed ID: 10449753
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The SH2 domain-containing protein tyrosine phosphatase SHP-1 is induced by granulocyte colony-stimulating factor (G-CSF) and modulates signaling from the G-CSF receptor.
    Ward AC; Oomen SP; Smith L; Gits J; van Leeuwen D; Soede-Bobok AA; Erpelinck-Verschueren CA; Yi T; Touw IP
    Leukemia; 2000 Jul; 14(7):1284-91. PubMed ID: 10914554
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors.
    Wu CJ; O'Rourke DM; Feng GS; Johnson GR; Wang Q; Greene MI
    Oncogene; 2001 Sep; 20(42):6018-25. PubMed ID: 11593409
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The emerging field of receptor-mediated inhibitory signaling: SHP or SHIP?
    Scharenberg AM; Kinet JP
    Cell; 1996 Dec; 87(6):961-4. PubMed ID: 8978600
    [No Abstract]   [Full Text] [Related]  

  • 54. New variations of human SHP-1.
    Matsushita M; Tsuchiya N; Oka T; Yamane A; Tokunaga K
    Immunogenetics; 1999 Jun; 49(6):577-9. PubMed ID: 10380707
    [No Abstract]   [Full Text] [Related]  

  • 55. The use of the yeast two hybrid system to evaluate ErbB-3 interactions with SH2 domain containing proteins.
    Yoo JY; Hamburger AW
    Biochem Biophys Res Commun; 1998 Oct; 251(3):903-6. PubMed ID: 9791008
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities.
    De Souza D; Fabri LJ; Nash A; Hilton DJ; Nicola NA; Baca M
    Biochemistry; 2002 Jul; 41(29):9229-36. PubMed ID: 12119038
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Regulation of the immune system by protein tyrosine phosphatases].
    Mizuno K; Yakura H
    Seikagaku; 2005 Oct; 77(10):1281-90. PubMed ID: 16296320
    [No Abstract]   [Full Text] [Related]  

  • 58. Kinetic comparison of the catalytic domains of SHP-1 and SHP-2.
    Niu T; Liang X; Yang J; Zhao Z; Zhou GW
    J Cell Biochem; 1999 Jan; 72(1):145-50. PubMed ID: 10025675
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Grb2 binding to the different isoforms of Ret tyrosine kinase.
    Alberti L; Borrello MG; Ghizzoni S; Torriti F; Rizzetti MG; Pierotti MA
    Oncogene; 1998 Sep; 17(9):1079-87. PubMed ID: 9764818
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SHP-2, SH2-containing protein tyrosine phosphatase-2.
    Stein-Gerlach M; Wallasch C; Ullrich A
    Int J Biochem Cell Biol; 1998 May; 30(5):559-66. PubMed ID: 9693956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.